Navigation Links
HIV Drug Might Spur Resistant Strains of Virus
Date:8/5/2008

Used during breast-feeding to prevent mom-to-baby transmission, nevirapine could have downside, study finds

TUESDAY, Aug. 5 (HealthDay News) -- The drug nevirapine -- widely used in developing countries to prevent transmission of HIV from mothers to babies -- persists in the breast milk and blood of mothers, a new Stanford University study finds.

That, in turn, could increase the risk that they and their children will develop drug-resistant strains of HIV, the researchers added.

The scientists looked at 32 HIV-positive pregnant women in Zimbabwe who received a single dose of nevirapine when they went into labor. The women had received no other treatment for their infection with HIV, the virus that causes AIDS.

Two weeks after delivery, more than half of the women still had detectable levels of the drug in their blood, and two-thirds had measurable levels of nevirapine in their breast milk. The longer the drug stays in the body, the more likely it is to develop drug-resistant mutations, the Stanford researchers said.

At the start of the study, none of the women had drug-resistant HIV strains. But two months after they gave birth, one-third of the women had drug-resistant strains in their blood, and 65 percent had drug-resistant strains in their breast milk as well, and could pass those strains to their babies during breast-feeding. Women with more advanced HIV were most likely to develop drug-resistant strains.

The study was expected to be presented Tuesday at the International AIDS Conference in Mexico City.

"In the short term, nevirapine is better than nothing. But in the long term, I'm concerned about conferring resistance. If you're talking about resistance on a broad scale, it could jeopardize future treatment for mothers and infants," principal investigator Dr. David Katzenstein, a professor of infectious diseases, said in a Stanford news release.

Nevirapine and another
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Fish Oil Might Help Relieve MS
2. HIV Drug Might Fight Cancer
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Vitamin C Plus Fat Might Spur Cancer
5. Mathematics might save you a trip to the ER
6. Veggies Might Ward Off Age-Linked Vision Woes
7. Rating your pain from 0 to 10 might not help your doctor
8. Blood Marker Might Help Spot Early Liver Cancer
9. Hushed Genes Might Mean Higher Lung Cancer Risk
10. Mathematics might save you a trip to the ER
11. More Prostate Cancers Might Be Prevented
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HIV Drug Might Spur Resistant Strains of Virus
HIV Drug Might Spur Resistant Strains of Virus
Breaking Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Health Insurance Options for Domestic Partnerships 51188 1Health Insurance Options for Domestic Partnerships 51188 2Health Insurance Options for Domestic Partnerships 51188 3Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 1Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 2Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 3Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 4Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 5Statement by Registered Dietitian and American Dietetic Association President Jessie M Pavlinac on Health Reform and Conservation of Natural Resource 51184 1Statement by Registered Dietitian and American Dietetic Association President Jessie M Pavlinac on Health Reform and Conservation of Natural Resource 51184 2